Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

Phase 4

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04087993Phase 3Withdrawn

Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients

Role: lead

NCT05276375Phase 2Completed

Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19

Role: lead

NCT04485325Phase 4Completed

Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

Role: lead

NCT05322889Phase 2Completed

Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)

Role: lead

NCT03148860Phase 3Completed

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA

Role: lead

NCT04161456Phase 2Completed

Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata

Role: lead

NCT02686788Phase 2Completed

TMP001 in Relapsing-remitting Multiple Sclerosis

Role: lead

All 7 trials loaded